{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:11:03Z","timestamp":1794352263099,"version":"4.9.0"},"reference-count":22,"publisher":"National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. oncol."],"abstract":"<jats:p>Background. miRNAs have emerged as promising biomarkers for breast cancer, particularly in predicting treatment response and prognosis. Their ability to regulate gene expression and their presence in various bodily fluids make them valuable tools for personalized medicine. Materials and Methods. The study was based on a retrospective analysis of the results of the examination, treatment, and survival of 94 patients with stage II\u2014III triple-negative breast cancer (TNBC) who underwent treatment at the Kyiv City Clinical Oncology Center during 2013\u20142017. miRNA expressions in blood serum were estimated using the real-time RT-PCR. Results. The elevated levels of miR-21, -155, -199a, and -200b (p &lt; 0.05) were linked to metastasis to regional lymph nodes, while miR-373 and -126 expression levels were associated with the tumor stage (r = 0.55 and 0.57, respectively, p &lt; 0.05). The higher serum levels of miR-21 (&gt; 5.4, p &lt; 0.05), -125b (&gt; 6.0, p &lt; 0.05) and the lower miR-205 levels (&lt; 2.0, p &lt; 0.05) were associated with the poorer response to line I and II neoadjuvant chemotherapy. The serum levels of miR-21, -125b, -126, -199a, -200b, -205, and -373 were found to correlate with the overall and recurrence-free survivals in TNBC patients. Conclusions. These findings suggest that miRNA-based biomarkers may have the potential as prognostic and predictive tools in TNBC, aiding in personalized treatment strategies.<\/jats:p>","DOI":"10.15407\/exp-oncology.2025.01.016","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T11:10:31Z","timestamp":1752664231000},"page":"16-23","source":"Crossref","is-referenced-by-count":1,"title":["\u0421IRCULATING MIRNAS AS PREDICTIVE MARKERS FOR LINE I AND II NEOADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER"],"prefix":"10.15407","volume":"47","author":[{"given":"T.","family":"BORIKUN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"BAZAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"ZADVORNYI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"KARACHAROVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YU.","family":"LYTOVCHENKO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"LUKIANOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"32237","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"13618","doi-asserted-by":"crossref","unstructured":"Bhushan A, Gonsalves A, Menon JU. Current state of breast cancer diagnosis, treatment, and theranostics. Pharma- ceutics. 2021;13(5):723. https:\/\/doi.org\/10.3390\/pharmaceutics13050723","DOI":"10.3390\/pharmaceutics13050723"},{"key":"13619","unstructured":"Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med."},{"key":"13620","doi-asserted-by":"crossref","unstructured":";23(1):1-16. https:\/\/doi.org\/10.1007\/s10238-021-00781-1","DOI":"10.1007\/s10238-021-00781-1"},{"key":"13621","unstructured":"Fuksa L, Micuda S, Grim J, et al. Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy."},{"key":"13622","doi-asserted-by":"crossref","unstructured":"Cancer Invest. 2012;30(9):663-678. https:\/\/doi.org\/10.3109\/07357907.2012.725441","DOI":"10.3109\/07357907.2012.725441"},{"key":"13623","unstructured":"Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant chemotherapy for breast cancer: past, present, and future."},{"key":"13624","doi-asserted-by":"crossref","unstructured":"Breast Cancer (Auckl). 2020;14:1178223420980377. https:\/\/doi.org\/10.1177\/1178223420980377","DOI":"10.1177\/1178223420980377"},{"key":"13625","doi-asserted-by":"crossref","unstructured":"Bou Zerdan M, Ghorayeb T, Saliba F, et al. Triple negative breast cancer: Updates on classification and treatment in 2021. Cancers (Basel). 2022;14(5):1253. https:\/\/doi.org\/10.3390\/cancers14051253","DOI":"10.3390\/cancers14051253"},{"key":"13626","doi-asserted-by":"crossref","unstructured":"Sabit H, Cevik E, Tombuloglu H, et al. Triple negative breast cancer in the era of miRNA. Crit Rev Oncol Hematol. 2021;157:103196. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103196","DOI":"10.1016\/j.critrevonc.2020.103196"},{"key":"13627","doi-asserted-by":"crossref","unstructured":"Sueta A, Fujiki Y, Goto-Yamaguchi L, et al. Exosomal miRNA profiles of triple-negative breast cancer in neoadju- vant treatment. Oncol Lett. 2021;22(6):819. https:\/\/doi.org\/10.3892\/ol.2021.13080","DOI":"10.3892\/ol.2021.13080"},{"key":"13628","doi-asserted-by":"crossref","unstructured":"Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S, Mokarian F. Plasma level of miR-21 and miR-451 in prima- ry and recurrent breast cancer patients. Breast Cancer (Dove Med Press). 2019;11:293-301. https:\/\/doi.org\/10.2147\/ BCTT.S224333","DOI":"10.2147\/BCTT.S224333"},{"key":"13629","doi-asserted-by":"crossref","unstructured":"Piasecka D, Braun M, Kordek R, Sadej R, Romanska H. MicroRNAs in regulation of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 2018;144(8):1401-1411. https:\/\/doi.org\/10.1007\/s00432-018-2689-2","DOI":"10.1007\/s00432-018-2689-2"},{"key":"13630","doi-asserted-by":"crossref","unstructured":"Zhang C, Sun C, Zhao Y, et al. Overview of microRNA as diagnostic and prognostic biomarkers for high-incidence cancers in 2021. Int J Mol Sci. 2022;23(19):11389. https:\/\/doi.org\/10.3390\/ijms231911389","DOI":"10.3390\/ijms231911389"},{"key":"13631","doi-asserted-by":"crossref","unstructured":"Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 2011;34(12):675-680. https:\/\/doi.org\/10.1159\/000334552","DOI":"10.1159\/000334552"},{"key":"13632","doi-asserted-by":"crossref","unstructured":"Wang XX, Ye FG, Zhang J, et al. Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by sup- pressing RUNX2. Cancer Manag Res. 2018;10:4393-4400. https:\/\/doi.org\/10.2147\/CMAR.S172205","DOI":"10.2147\/CMAR.S172205"},{"key":"13633","doi-asserted-by":"crossref","unstructured":"Qattan A, Al-Tweigeri T, Alkhayal W, et al. Clinical identification of dysregulated circulating micrornas and their implication in drug response in triple negative breast cancer (TNBC) by Target Gene Network and Meta-Analysis. Genes (Basel). 2021;12(4):549. https:\/\/doi.org\/10.3390\/genes12040549","DOI":"10.3390\/genes12040549"},{"key":"13634","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Vazquez R, Ruiz-Garc\u00eda E, Meneses Garc\u00eda A, et al. A microRNA signature associated with patho- logical complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol. 201;39(6):1010428317702899. https:\/\/doi.org\/10.1177\/1010428317702899","DOI":"10.1177\/1010428317702899"},{"key":"13635","unstructured":"Chekhun V, Mushii O, Zadvornyi T, et al. Features of COL1A1 expression in breast cancer tissue of young patients."},{"key":"13636","doi-asserted-by":"crossref","unstructured":"Exp Oncol. 2023;45(3):351-363. https:\/\/doi.org\/10.15407\/exp-oncology.2023.03.351","DOI":"10.15407\/exp-oncology.2023.03.351"},{"key":"13637","doi-asserted-by":"crossref","unstructured":"Santana T, de Oliveira Passamai L, de Miranda FS, et al. The role of miRNAs in the prognosis of triple-negative breast cancer: a systematic review and meta-analysis. Diagnostics (Basel). 2022;13(1):127. https:\/\/doi.org\/10.3390\/ diagnostics13010127","DOI":"10.3390\/diagnostics13010127"},{"key":"13638","doi-asserted-by":"crossref","unstructured":"Pucci P, Rescigno P, Sumanasuriya S, et al. Hypoxia and noncoding RNAs in taxane resistance. Trends Pharmacol Sci. 2018;39(8):695-709. https:\/\/doi.org\/10.1016\/j.tips.2018.05.002","DOI":"10.1016\/j.tips.2018.05.002"},{"key":"13639","doi-asserted-by":"crossref","unstructured":"Shao B, Wang X, Zhang L, et al. Plasma microRNAs predict chemoresistance in patients with metastatic breast can- cer. Technol Cancer Res Treat. 2019;18:1533033819828709. https:\/\/doi.org\/10.1177\/1533033819828709","DOI":"10.1177\/1533033819828709"}],"container-title":["Experimental Oncology"],"original-title":[],"link":[{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/461\/398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/461\/398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T11:11:04Z","timestamp":1752664264000},"score":1,"resource":{"primary":{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/view\/461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.15407\/exp-oncology.2025.01.016","relation":{},"ISSN":["2312-8852","1812-9269"],"issn-type":[{"value":"2312-8852","type":"electronic"},{"value":"1812-9269","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}